NRXP

Company Overview — What Does NRX Pharmaceuticals, Inc. Do?

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware. NRX Pharmaceuticals, Inc. (NRXP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Stephen H. Willard. With a market capitalization of $71M, NRXP is one of the notable companies in the Healthcare sector.

NRX Pharmaceuticals, Inc. (NRXP) Stock Rating — Reduce (April 2026)

As of April 2026, NRX Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 23.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NRXP ranks #3,863 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NRX Pharmaceuticals, Inc. ranks #655 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NRXP Stock Price and 52-Week Range

NRX Pharmaceuticals, Inc. (NRXP) currently trades at $2.23. The stock lost $0.03 (1.1%) in the most recent trading session. The 52-week high for NRXP is $3.84, which means the stock is currently trading -41.8% from its annual peak. The 52-week low is $1.58, putting the stock 41.4% above its annual trough. Recent trading volume was 477K shares, suggesting relatively thin trading activity.

Is NRXP Overvalued or Undervalued? — Valuation Analysis

NRX Pharmaceuticals, Inc. (NRXP) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 304.71x, compared to 1.66x for the average Healthcare stock.

At current multiples, NRX Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NRX Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

NRX Pharmaceuticals, Inc. (NRXP) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 100.6%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -284.7% versus the sector average of -33.1%.

On a margin basis, NRX Pharmaceuticals, Inc. reports gross margins of 59.9%, compared to 71.5% for the sector. The operating margin is -1662.8% (sector: -66.1%). Net profit margin stands at -2433.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NRXP Debt, Balance Sheet, and Financial Health

NRX Pharmaceuticals, Inc. has a debt-to-equity ratio of -17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.31x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $4M. Cash and equivalents stand at $7M.

NRXP has a beta of 1.18, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NRX Pharmaceuticals, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NRX Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NRX Pharmaceuticals, Inc. reported revenue of $242,000 and earnings per share (EPS) of $-1.34. Net income for the quarter was $-37M. Gross margin was 59.9%. Operating income came in at $-19M.

In FY 2025, NRX Pharmaceuticals, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.34. Net income for the quarter was $-29M. Gross margin was 58.8%. Operating income came in at $-16M.

In Q3 2025, NRX Pharmaceuticals, Inc. reported revenue of $242,000 and earnings per share (EPS) of $-0.27. Net income for the quarter was $-6M. Gross margin was 59.9%. Operating income came in at $-4M.

In Q2 2025, NRX Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.98. Net income for the quarter was $-18M. Operating income came in at $-4M.

Over the past 8 quarters, NRX Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $242,000. Investors analyzing NRXP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NRXP Dividend Yield and Income Analysis

NRX Pharmaceuticals, Inc. (NRXP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NRXP Momentum and Technical Analysis Profile

NRX Pharmaceuticals, Inc. (NRXP) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

NRXP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NRX Pharmaceuticals, Inc. (NRXP) ranks #655 out of 838 stocks based on the Blank Capital composite score. This places NRXP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NRXP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NRXP vs S&P 500 (SPY) comparison to assess how NRX Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

NRXP Next Earnings Date

No upcoming earnings date has been announced for NRX Pharmaceuticals, Inc. (NRXP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NRXP? — Investment Thesis Summary

The quantitative profile for NRX Pharmaceuticals, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 29/100) increases portfolio risk.

In summary, NRX Pharmaceuticals, Inc. (NRXP) earns a Reduce rating with a composite score of 23.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NRXP stock.

Related Resources for NRXP Investors

Explore more research and tools: NRXP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NRXP head-to-head with peers: NRXP vs AZN, NRXP vs SLGL, NRXP vs VMD.